86268-06-6 Usage
Uses
Used in Pharmaceutical Industry:
BAY 13-9952 is used as a potential therapeutic agent for the treatment of cancer and neurological disorders due to its diverse biological activities and potential as a tyrosine kinase inhibitor. Its specific mechanisms of action and potential therapeutic uses are currently being explored through preclinical and clinical research.
Used in Cancer Treatment:
BAY 13-9952 is used as a tyrosine kinase inhibitor, which could make it useful in the treatment of certain types of cancer. Tyrosine kinases are enzymes that play a crucial role in cell signaling, and their abnormal activity is often associated with cancer development and progression. By inhibiting these enzymes, BAY 13-9952 may help in controlling cancer cell growth and proliferation.
Used in Neurological Disorder Treatment:
BAY 13-9952 is also being investigated for its potential use in treating neurological disorders. Its anti-inflammatory properties may contribute to the management of conditions such as neuroinflammation, which is a common feature in various neurological disorders.
Check Digit Verification of cas no
The CAS Registry Mumber 86268-06-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,6,2,6 and 8 respectively; the second part has 2 digits, 0 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 86268-06:
(7*8)+(6*6)+(5*2)+(4*6)+(3*8)+(2*0)+(1*6)=156
156 % 10 = 6
So 86268-06-6 is a valid CAS Registry Number.
86268-06-6Relevant academic research and scientific papers
Action d'organolithiens sur la methyl-2 quinoxaline. Etude de la reactivite des adduits
Mettey, Yvette,Vierfond, Jean-Michel,Thal, Claude,Miocque, Marcel
, p. 133 - 137 (2007/10/02)
The action of organolithium reagents such as phenyllithium or n-butyllithium on 2-methylquinoxaline gave lithiation of the methyl group which upon reaction with electrophiles produce side chain alkenyl derivatives.On the other hand organolithium reagents react with the quinoxaline azomethine bond to give 1-lithio-2-alkyl(or aryl)-3-methylquinoxalines which can be further lithiated on the methyl group to give 2-alkyl(or aryl)-3-alkenylquinoxaline derivatives.The adducts can be condensed with electrophiles such as benzonitrile or methyl benzoate but only methyl benzoate leads to N condensed derivatives.Furthermore substituted 1,2,3,4-tetraquinoxalines are available via the above lithio intermediates.
